# US 2024/0002880 A1 · Controllable Transcription

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0002880 A1
- Document ID: US20240002880A1
- Status: Published application
- Kind: A1
- Application number: 18/203,913
- Filed: 2023-05-31
- Published: 2024-01-04
- Earliest claimed: 2016-11-24
- Assignees: Cambridge Enterprise Limited (GB/GB)
- Applicants: Cambridge Enterprise Limited (GB/GB)
- Inventors: Ludovic Vallier; Mark Kotter; Matthias Pawlowski; Alessandro Bertero; Daniel Ortmann
- Web page: https://patentgrep.com/patent/US20240002880A1

## CPC

- C12N 15/85: for animal cells
- C12N 15/86: Viral vectors
- A61K 35/545: Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 5/0606: {Pluripotent embryonic cells, e.g. embryonic stem cells [ES] (embryonic germ cells C12N5/0611, induced pluripotent stem cells C12N5/0696)}
- C12N 5/0607: {Non-embryonic pluripotent stem cells, e.g. MASC (induced pluripotent stem cells C12N5/0696)}
- C12N 5/0622: {Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells}
- C12N 5/0658: {Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts}
- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- G01N 33/5005: {involving human or animal cells (immunoassay G01N33/56966; immunoassays of protozoa G01N33/56905; protozoa in screening assays C12Q1/025)}
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2501/999: Small molecules not provided for elsewhere
- C12N 2506/02: from embryonic cells
- C12N 2506/03: from non-embryonic pluripotent stem cells
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N 2800/80: Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
- C12N 2830/003: tet inducible
- G01N 2800/00: Detection or diagnosis of diseases
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention relates to a stable method for introducing at least one inducible cassette into a cell, and permitting controllable transcription from within that inducible cassette. The method may be used for any cell type, from any eukaryotic organism, but has a particular application in the introduction of inducible cassettes into pluripotent stem cells, such as animal or human pluripotent stem cells (hPSCs). The inducible cassette is controllably inserted in such a way to ensure that the genetic material it contains is not silenced or subject to negative influences from the insertion site, and transcription of the genetic material is controlled.

## Claims

### Claim 1

A method for production of adipocytes from pluripotent stem cells, comprising the steps of:
a) inserting a gene encoding a transcriptional regulator protein into a first genetic safe harbour site; and
b) inserting a gene encoding an adipocyte lineage master regulator operably linked to an inducible promoter into a second genetic safe harbour site;
wherein said inducible promoter is regulated by the transcriptional regulator protein;
wherein said first and second genetic safe harbour sites are different; and
wherein the pluripotent stem cell is an animal cell.

### Claim 2 (depends on 1)

The method of claim 1, wherein the animal cell is a mammalian, marsupial, non-human primate, camelid, or livestock animal cell.

### Claim 3 (depends on 1)

The method of claim 1, wherein the animal cell is from a livestock animal.

### Claim 4 (depends on 1)

The method of claim 1, wherein the animal cell is from a pig or from cattle.

### Claim 5 (depends on 1)

The method of claim 1, wherein the method is for programming of the pluripotent stem cell into a mature cell.

### Claim 6 (depends on 1)

The method of claim 1, wherein the method is for programming of the pluripotent stem cell into an adipocyte.

### Claim 7 (depends on 1)

The method of claim 1, wherein the transcriptional regulator protein is selected from the group consisting of: a reverse tetracycline transactivator protein (rtTa), a Tetracycline repressor (TetR), a VgEcR synthetic receptor, a hybrid transcriptional regulator protein comprising a DNA binding domain from yeast GAL4 protein, a truncated ligand binding domain from the human progesterone receptor, and an activation domain from human NF-κB.

### Claim 8 (depends on 7)

The method of claim 7, wherein activity of the rtTA is controlled by tetracycline or a derivative thereof.

### Claim 9 (depends on 7)

The method of claim 7, wherein activity of the rtTA is controlled by doxycycline.

### Claim 10 (depends on 1)

The method of claim 1, the inducible promoter includes a Tet Responsive Element (TRE).

### Claim 11 (depends on 1)

The method of claim 1, wherein the first and second genomic safe harbour sites are selected from any two of a hROSA26 locus, a AAVS1 locus, a CLYBL gene, or a CCR5 gene.

### Claim 12 (depends on 1)

The method of claim 1, wherein additional genetic material is inserted at the first and/or second genomic safe harbour sites.

### Claim 13 (depends on 12)

The method of claim 12, wherein the additional genetic material is selected from the group consisting of:
a) suicide gene;
b) selectable marker;
c) reporter gene; and
d) gene for a non-coding RNA.

### Claim 14 (depends on 1)

A cell obtained by the method of claim 1.

### Claim 15

(canceled)

### Claim 16

(canceled)

### Claim 17

(canceled)
